期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 81, 期 1, 页码 104-107出版社
MOSBY-ELSEVIER
DOI: 10.1038/sj.clpt.6100017
关键词
-
A consistent framework for the acceptance and qualification of biomarkers for regulatory use is needed to facilitate innovative and efficient research and subsequent application of biomarkers in drug development. One key activity is biomarker qualification, a graded, fit-for-purpose evidentiary process linking a biomarker with biology and clinical end points. A biomarker consortium model win distribute cost and risk, and drive efficient execution of research and ultimately regulatory acceptance of biomarkers for specific indications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据